share_log

AbbVie | DEFA14A: Others

AbbVie | DEFA14A: Others

艾伯维公司 | DEFA14A:其他
SEC announcement ·  03/18 16:22
Moomoo AI 已提取核心信息
AbbVie Inc., a biopharmaceutical company, has filed a definitive additional materials proxy statement with the United States Securities and Exchange Commission (SEC). This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that AbbVie is preparing materials related to upcoming corporate matters that may require a vote by shareholders. The proxy statement is not preliminary and does not require a filing fee, suggesting that it is ready for review by shareholders and the SEC. The document is intended for use in connection with the company's forthcoming decisions and does not constitute soliciting material under §240.14a-12.
AbbVie Inc., a biopharmaceutical company, has filed a definitive additional materials proxy statement with the United States Securities and Exchange Commission (SEC). This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that AbbVie is preparing materials related to upcoming corporate matters that may require a vote by shareholders. The proxy statement is not preliminary and does not require a filing fee, suggesting that it is ready for review by shareholders and the SEC. The document is intended for use in connection with the company's forthcoming decisions and does not constitute soliciting material under §240.14a-12.
生物制药公司艾伯维公司(AbbVie Inc.)已向美国证券交易委员会(SEC)提交了明确的附加材料委托书。根据1934年《证券交易法》第14(a)条提交的这份文件表明,艾伯维正在准备与即将发生的可能需要股东投票的公司事务有关的材料。委托书不是初步的,不需要申请费,这表明它已准备好供股东和美国证券交易委员会审查。该文件旨在与公司即将作出的决定相关使用,不构成第240.14a-12条规定的招标材料。
生物制药公司艾伯维公司(AbbVie Inc.)已向美国证券交易委员会(SEC)提交了明确的附加材料委托书。根据1934年《证券交易法》第14(a)条提交的这份文件表明,艾伯维正在准备与即将发生的可能需要股东投票的公司事务有关的材料。委托书不是初步的,不需要申请费,这表明它已准备好供股东和美国证券交易委员会审查。该文件旨在与公司即将作出的决定相关使用,不构成第240.14a-12条规定的招标材料。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息